✦ LIBER ✦

Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics

✍ Scribed by Zheng Yang; Lisa Zadjura; Celia D'Arienzo; Anthony Marino; Kenneth Santone; Lewis Klunk; Douglas Greene; Pin-Fang Lin; Richard Colonno; Tao Wang; Nicholas Meanwell; Steven Hansel

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 207 KB
Volume: 26
Category: Article
ISSN: 0142-2782
DOI: 10.1002/bdd.471

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Utilization of in vitro Caco-2 permeabil

Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties

✍ Zheng Yang; Lisa M. Zadjura; Anthony M. Marino; Celia J. D'Arienzo; Jacek Malino 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 230 KB

Optimizing pharmacokinetic properties to improve oral exposure is a common theme in modern drug discovery. In the present work, in vitro Caco-2 permeability and microsomal half-life screens were utilized in an effort to guide the structure-activity relationship in order to improve the pharmacokineti

Pharmacokinetics of a novel HIV-1 protea

Pharmacokinetics of a novel HIV-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice

✍ Jean-Christophe Leroux; Eric Doelker; Robert Gurny; Robert Cozens; Johannes L. R 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 562 KB

Preclinical pharmacokinetics and metabol

Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38α inhibitor: identification of an active metabolite in preclinical species and human liver microsomes

✍ Amit S. Kalgutkar; Heather L. Hatch; Frederick Kosea; Hang T. Nguyen; Edna F. Ch 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 406 KB 👁 2 views

Development and validation of a high-per

Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study

✍ Federica Sala; Elena Marangon; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maur 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Abstract CEP‐18770, [(1__R__)‐1‐{[(2__S__,3__R__)‐3‐hydroxy‐2‐{[(6‐phenyl‐2‐pyridinyl)carbonyl]amino}butanoyl]amino}‐3‐methylbutyl]boronic acid, is a novel proteasome inhibitor, now under early clinical evaluation as an anticancer agent. To investigate its clinical pharmacokinetics, a high‐perfo

Development and validation of a high-per

Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study

✍ Federica Sala; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maurizio D'Incalci; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

E‐3810, 6‐[[7‐[(1‐aminocyclopropyl)methoxy]‐6‐methoxy‐4‐quinolyl]oxy]‐__N__‐methyl‐naphthalene‐1‐carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anti